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Dr Michael Mack (Dallas, Tex). You have performed a study that
is potentially a landmark one and likely to change the landscape of
the management of patients with critical aortic stenosis in the future.
I believe this study is that important. First, similar to the study by
Sarano in patients with asymptomatic mitral regurgitation, deter-
mining that an effective regurgitant orifice greater than 40 led to de-
creased survival, your study has defined some characteristics that
may lead to earlier operative management of patients with aortic ste-
nosis. Second, you have lent further clarity to the issue of patient–
prosthetic mismatch and perhaps saved some elderly patients from
undergoing the added risk of a root-enlarging procedure. You con-
clude that LV hypertrophy, LV dysfunction, extremely severe aortic
stenosis, older age, and a small prosthesis in younger patients de-
creased survival.1278 The Journal of Thoracic and Cardiovascular Surgery c JHowever, just as a movie critic needs to find something wrong
with a movie to maintain credibility as a critic, I can’t let you off
scot-free. The positive aspects your study include the fact that it is
a large study of more than 3000 patients who received a single
type of valve with a mean follow-up of 5 years. A sophisticated sta-
tistical analysis (and thank you for the explanation of the Z value) to
minimize confounding variables lends further clarity to the data.
However, this is not a population with isolated pure aortic stenosis,
with 56% of the patients having undergone concomitant coronary
bypass surgery and 35% of patients also having aortic regurgitation,
factors known to affect outcomes. In addition, only 13% of the pa-
tients were actually asymptomatic, yet significant management con-
clusions are drawn from this group.
My specific questions are as follows. First, you defined a small
prosthesis as a patient–prosthesis Z value of21.5, which corresponds
to 1.5 standard deviations below normal valve size for patient body
surface area. Why did you pick that Z value rather than perhaps 1 or 2?
Second, do you think that analysis of a population in whommore
than half of the patients underwent coronary artery bypass grafting
and one third of the patients had aortic regurgitation is valid for iso-
lated pure aortic stenosis?
Third, we now make clinical decisions in patients with asymp-
tomatic mitral regurgitation on the basis of an effective regurgitant
orifice greater than 40. Surgeons are familiar with echocardio-
graphic parameters of AV area, peak and mean gradients, jet veloc-
ity, and EF for making decisions. Should we now include an LV
mass index of greater than 135 in men or greater than 100 in women
as an indication for surgery in patients with critical aortic stenosis?
Four, as surgeons, we always want to know what to do different
when we go home. We use the red, yellow, green charts to choose
valve size now based on patient body surface area. Do your data
mean that we should now ignore those color charts for elderly patients?
Fifth, you state that guidelines should be changed to recommend
earlier AVR in asymptomatic patients, yet current guidelines, class
IIb, already recommend AVR in asymptomatic patients with either
an abnormal exercise test, likelihood of rapid progression based on
age, calcification and coronary artery disease, or extremely severe
aortic stenosis with a valve area of less than 0.6 cm2. How specifi-
cally would you recommend these current guidelines be changed?
Last, is it possible to come up with a patient management algo-
rithm factoring in all the variables you have identified, including
age, severity of aortic stenosis, LV dysfunction, LV mass index,
to guide the timing of surgical interventions?
Dr Mihaljevic. The first question was why did we define a Z
value of 21.5 as a cutoff? That was not truly a deliberate decision.
That was a result of an observation that by the Z value of 21.5 and
less, we noted the detrimental effects of the patient–prosthesis mis-
match that truly affected the outcomes of our patients, in particular
in those patients who had severe LV hypertrophy.
Your second question was whether we think that the analysis of
the population in whom more than 50% of patients underwent cor-
onary artery bypass grafting and one third of patients had severe aor-
tic regurgitation is truly representative of typical patients with aortic
stenosis. We think this is definitely the case. We purposely included
these patients, because when patients present to a surgeon or a cardi-
ologist with aortic stenosis, this is what typical patients look like.
These are the patients who almost always have some degree of aortic
regurgitation, but we were careful to exclude patients in whom the
aortic regurgitation was a predominant pathology. Furthermore, itune 2008
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disease. The median age of patients in our study was 71 years, so
those patients are most likely going to have coronary artery disease,
and those are the patients we are going to see referred to us for aortic
stenosis. We don’t know if the coronary artery disease is present up
front until they undergo a coronary angiogram. We are currently
conducting a study in which we are particularly studying the effect
of coronary artery disease in patients and their outcomes when they
have severe aortic stenosis. Our preliminary findings show that the
presence of coronary artery disease triggers the symptoms in pa-
tients with aortic stenosis much earlier in the course, and those pa-
tients almost never develop severe LV hypertrophy, because they
become symptomatic much sooner in the course of their illness.
Your third question was regarding the echocardiographic param-
eters and whether we should use the LV mass index of greater than
135 as an indicator for surgery. I would absolutely concur with this
statement. We as surgeons have to be familiar with new echocardio-
graphic measurements, and just as you mentioned an example of mi-
tral valve surgery, I think we have to pay particular attention to the
ventricular effects of valvular heart disease. Ultimately all untreated
patients with aortic stenosis die not because their aortic stenosis gets
worse but because the effects of the aortic stenosis on the ventricle
caused it to fail. The presence of severe LV hypertrophy should not
any longer be viewed as a benign side effect of aortic stenosis, which
will be reversed after we replace the AV, but a significant contribu-
tor in the pathology or bad outcomes of these patients even after
a successful operation.
Your fourth question related to the sizes of the AV prostheses
that should be used for elderly patients with severe aortic stenosis.
As you saw from our presentation here, if we take a look at the entire
population of patients with aortic stenosis and compare those who
have severe patient–prosthesis mismatch with those who have pros-
theses that are larger than their anticipated AV area (standard AV
area), their overall survival is fairly similar. When we look at pa-
tient–prosthesis mismatch, we have to look at the different ages ofThe Journal of Thorathe patients undergoing operation, and in an elderly patient, the sur-
vival is truly not affected by a smaller prosthesis. So even implanta-
tion of a relatively small prosthesis was sufficient enough to relieve
the gradient to the extent that it was beneficial to survival. If we take
a look at our curves of survival of elderly patients, they benefited the
most from AVR. Their survival is better than the expected survival
of their matched cohorts, in contrast with our younger patients.
The fifth question is an important question about the current
guidelines and class IIb indications for AVR for asymptomatic pa-
tients. In our opinion, some of these class IIb indications should
be class I indications. For example, AV stenosis with an AV orifice
area of20.6 and a high gradient of 60 should truly be an indication
for surgery based on our data. As you can see from the curves shown
previously, patients with severe aortic stenosis and high gradients
did poorly, even after initial successful surgery. If we take a critical
look at the criteria that was used for the medical management, for
example, of patients with asymptomatic aortic stenosis, all articles
had a series with no more than 150 patients, with a follow-up that
was not more than 1.5 to 2 years. The longest observed survival
in patients with severe aortic stenosis who were asymptomatic and
underwent medical management was 67% 1-year event-free sur-
vival. The survival of patients who undergo surgery in the same con-
dition is approximately 10% to 15% better after the first year.
Obviously, they lack long-term follow-up because most of the pa-
tients develop symptoms anyhow and undergo surgery.
We hope that this article is going to be a significant contribution
to influence a change in the guidelines for treatment of patients with
asymptomatic aortic stenosis.
Your last question was, is it possible to come up with a patient
management algorithm to include all the risk factors and come up
with a new management scheme? Yes, absolutely. What we have
to take into consideration now is no longer only the AV orifice
area and gradients but also the degree of the LV hypertrophy, the
age of the patients, and the degree of the LV dysfunction at the
time of surgery, which most of us have been doing intuitively.cic and Cardiovascular Surgery c Volume 135, Number 6 1279
